Novartis has opened a 10,000ft² radioligand therapy (RLT) manufacturing facility in Carlsbad in the US state of California, as part of its $23bn investment in the country’s infrastructure up to 2030.
SanegeneBio has formed a worldwide research and licensing partnership with Eli Lilly and Company to develop RNAi [RNA interference] candidates for metabolic diseases.
Alvotech and Advanz Pharma have announced the receipt of marketing authorisations from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for all four formulations of Gobivaz – Alvotech’s biosimilar to Simponi (golimumab).
AmacaThera has entered into an exclusive worldwide licensing agreement with Pacira BioSciences for up to $230m for AMT-143, an investigational long-acting non-opioid anaesthetic.
Naobios and Tokyo Metropolitan Institute of Medical Science (TMIMS) have announced a partnership for the development of a new mpox vaccine using a live-attenuated approach.
Tempus has entered into a collaboration with Whitehawk to enhance biomarker-driven research and facilitate the development of Whitehawk's oncology pipeline.
iQure has formed a research partnership with University of Padova associate professor Laura Civiero to investigate iQ-007, the company's lead programme targeting EAAT2, the transporter responsible for glutamate uptake.
AeroRx Therapeutics has secured $21m in Series A financing, led by Avalon BioVentures, with participation from Alexandria Venture Investments, Correlation Ventures, and other investors.
The US Food and Drug Administration (FDA) has awarded Fast Track designation to Alto Neuroscience’s ALTO-101, a novel small molecule phosphodiesterase-4 (PDE4) inhibitor for the treatment of cognitive impairment linked to schizophrenia (CIAS).
BioLineRx and Hemispherian have formed a joint venture to advance the development of GLIX1, an oral small molecule aimed at targeting DNA damage response in glioblastoma (GBM) and other types of cancer.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.